Published in Clin Cancer Res on July 15, 2004
Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm (2008) 1.45
Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer. Colloids Surf B Biointerfaces (2011) 1.14
Production and characterization of a peptide-based monoclonal antibody against CD44 variant 6. Monoclon Antib Immunodiagn Immunother (2015) 1.00
Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res (2009) 0.99
Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes. Mol Pharm (2011) 0.95
Targeting histone deacetylases for the treatment of disease. J Cell Mol Med (2008) 0.94
Prognostic significance of CD44s expression in resected non-small cell lung cancer. BMC Cancer (2011) 0.94
Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. ACS Nano (2014) 0.92
Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma. J Cancer Res Clin Oncol (2010) 0.91
Histone acetyltransferase PCAF up-regulated cell apoptosis in hepatocellular carcinoma via acetylating histone H4 and inactivating AKT signaling. Mol Cancer (2013) 0.91
Deacetylase inhibitors - focus on non-histone targets and effects. World J Biol Chem (2010) 0.90
Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc Natl Acad Sci U S A (2009) 1.72
Term Amniotic membrane is a high throughput source for multipotent Mesenchymal Stem Cells with the ability to differentiate into endothelial cells in vitro. BMC Dev Biol (2007) 1.71
An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. Biomacromolecules (2005) 1.70
Structural effects on the biodistribution and positron emission tomography (PET) imaging of well-defined (64)Cu-labeled nanoparticles comprised of amphiphilic block graft copolymers. Biomacromolecules (2007) 1.51
A review on usnic acid, an interesting natural compound. Naturwissenschaften (2002) 1.43
Real-time imaging and kinetics measurements of focused ultrasound-induced extravasation in skeletal muscle using SPECT/CT. J Control Release (2013) 1.41
Facile, efficient approach to accomplish tunable chemistries and variable biodistributions for shell cross-linked nanoparticles. Biomacromolecules (2008) 1.40
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J Med Chem (2005) 1.35
Hyaluronan mixed esters of butyric and retinoic Acid drive cardiac and endothelial fate in term placenta human mesenchymal stem cells and enhance cardiac repair in infarcted rat hearts. J Biol Chem (2007) 1.35
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood (2010) 1.34
In vivo evaluation of (64)Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent. Bioconjug Chem (2010) 1.24
Metal-based antitumour drugs in the post genomic era. Dalton Trans (2006) 1.24
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res (2007) 1.21
Ruthenium antimetastatic agents. Curr Top Med Chem (2004) 1.20
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. Int J Oncol (2008) 1.18
Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PLoS One (2010) 1.16
Labeling of Polymer Nanostructures for Medical Imaging: Importance of crosslinking extent, spacer length, and charge density. Macromolecules (2007) 1.15
Synthesis and characterization of core-shell star copolymers for in vivo PET imaging applications. Biomacromolecules (2008) 1.10
Molecular imaging of atherosclerotic plaque with (64)Cu-labeled natriuretic peptide and PET. J Nucl Med (2009) 1.09
A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res (2008) 1.06
Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)2Cl2] (L= o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru(azpy)2Cl2]. J Biol Inorg Chem (2004) 1.05
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. Dalton Trans (2011) 1.05
Half-sandwich Ru II[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: preparation, structural characterization and in vitro cytotoxic activity. J Inorg Biochem (2008) 1.02
Click to release: instantaneous doxorubicin elimination upon tetrazine ligation. Angew Chem Int Ed Engl (2013) 1.01
Folate-mediated Cell Uptake of Shell-crosslinked Spheres and Cylinders. J Polym Sci A Polym Chem (2008) 1.01
Metal-based inhibition of poly(ADP-ribose) polymerase--the guardian angel of DNA. J Med Chem (2011) 0.97
Butyric and retinoic mixed ester of hyaluronan. A novel differentiating glycoconjugate affording a high throughput of cardiogenesis in embryonic stem cells. J Biol Chem (2004) 0.96
Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity. Int J Oncol (2002) 0.95
In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. Mol Imaging (2009) 0.94
MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications suppresses KRAS in pancreatic cancer cells and delays tumor growth in mice. Nucleic Acids Res (2013) 0.94
Technetium-99m labelled fluconazole and antimicrobial peptides for imaging of Candida albicans and Aspergillus fumigatus infections. Eur J Nucl Med Mol Imaging (2002) 0.94
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Invest New Drugs (2014) 0.94
Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. Clin Cancer Res (2003) 0.93
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica (2012) 0.91
MicroPET imaging of MCF-7 tumors in mice via unr mRNA-targeted peptide nucleic acids. Bioconjug Chem (2005) 0.91
Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity. Biochem Pharmacol (2012) 0.91
Mesenchymal stem cells in renal function recovery after acute kidney injury: use of a differentiating agent in a rat model. Cell Transplant (2010) 0.90
The proline-rich peptide Bac7(1-35) reduces mortality from Salmonella typhimurium in a mouse model of infection. BMC Microbiol (2010) 0.90
Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms. J Med Chem (2007) 0.90
The anti-metastatic agent imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway. Arch Biochem Biophys (2002) 0.89
C1q as a unique player in angiogenesis with therapeutic implication in wound healing. Proc Natl Acad Sci U S A (2014) 0.89
An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. Curr Pharm Des (2008) 0.88
Histone deacetylase inhibitors for treatment of hepatocellular carcinoma. Acta Pharmacol Sin (2005) 0.88
Hyaluronan esters drive Smad gene expression and signaling enhancing cardiogenesis in mouse embryonic and human mesenchymal stem cells. PLoS One (2010) 0.87
Placental stem cells pre-treated with a hyaluronan mixed ester of butyric and retinoic acid to cure infarcted pig hearts: a multimodal study. Cardiovasc Res (2011) 0.87
Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation. Eur J Biochem (2002) 0.87
Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate. Nucl Med Biol (2009) 0.87
Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic use. J Antimicrob Chemother (2002) 0.86
Radiochemical and biological characteristics of 99mTc-UBI 29-41 for imaging of bacterial infections. Nucl Med Biol (2002) 0.86
Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. Dalton Trans (2007) 0.86
Linking the future of anticancer metal-complexes to the therapy of tumour metastases. Chem Soc Rev (2015) 0.85
New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. PLoS One (2013) 0.85
Ruthenium-porphyrin conjugates with cytotoxic and phototoxic antitumor activity. J Med Chem (2010) 0.85
Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes. J Med Chem (2006) 0.84
Evaluation of 111In-labeled EPep and FibPep as tracers for fibrin SPECT imaging. Mol Pharm (2013) 0.83
Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis. Eur J Clin Pharmacol (2010) 0.83
Long-term evaluation of TiO2-based 68Ge/68Ga generators and optimized automation of [68Ga]DOTATOC radiosynthesis. Appl Radiat Isot (2012) 0.83
The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation. J Inorg Biochem (2004) 0.83
Hyaluronan mixed esters of butyric and retinoic acid affording myocardial survival and repair without stem cell transplantation. J Biol Chem (2010) 0.83
Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation. J Biol Inorg Chem (2008) 0.83
Platinum(II) complexes with antitumoral/antiviral aromatic heterocycles: effect of glutathione upon in vitro cell growth inhibition. J Med Chem (2005) 0.82
Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica (2002) 0.82
Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: a preclinical study. Invest New Drugs (2004) 0.82
Hyaluronic acid butyric esters in cancer therapy. Anticancer Drugs (2005) 0.82
Preclinical combination therapy of the investigational drug NAMI-A(+) with doxorubicin for mammary cancer. Invest New Drugs (2014) 0.81
Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma. Curr Clin Pharmacol (2010) 0.81
Nitric oxide-mediated activity in anti-cancer photodynamic therapy. Nitric Oxide (2013) 0.81
Profiling the molecular mechanism of fullerene cytotoxicity on tumor cells by RNA-seq. Toxicology (2013) 0.81
Prospective monocentric study of non-tunnelled central venous catheter-related complications in hematological patients. Leuk Lymphoma (2008) 0.81
The PDT activity of free and pegylated pheophorbide a against an amelanotic melanoma transplanted in C57/BL6 mice. Invest New Drugs (2012) 0.80
Ruthenium anticancer drugs. Met Ions Biol Syst (2004) 0.80
Flow cytometry vs cytomorphology for the detection of hematologic malignancy in body cavity fluids. Leuk Res (2010) 0.80
Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenanthrolines and acyclovir or penciclovir. J Inorg Biochem (2004) 0.80
Anticancer activity of cationic porphyrins in melanoma tumour-bearing mice and mechanistic in vitro studies. Mol Cancer (2014) 0.80
Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. J Hematol Oncol (2014) 0.80
Electrochemical measurements confirm the preferential bonding of the antimetastatic complex [ImH][RuCl(4)(DMSO)(Im)] (NAMI-A) with proteins and the weak interaction with nucleobases. J Inorg Biochem (2004) 0.79
Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines. J Pharmacol Exp Ther (2003) 0.79
Molecular structure, solution chemistry and biological properties of the novel [ImH][trans-IrCl(4)(Im)(DMSO)], (I) and of the orange form of [(DMSO)(2)H][trans-IrCl(4)(DMSO)(2)], (II), complexes. J Inorg Biochem (2003) 0.79
SPECT imaging of fibrin using fibrin-binding peptides. Contrast Media Mol Imaging (2013) 0.79
Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells. Cancer Chemother Pharmacol (2002) 0.78
Detection of sites of infection in mice using 99mTc-labeled PN(2)S-PEG conjugated to UBI and 99mTc-UBI: a comparative biodistribution study. Nucl Med Biol (2009) 0.78
Molecular imaging of cancer with radiolabeled peptides and PET. Anticancer Agents Med Chem (2012) 0.78
Solution, solid state and biological characterization of ruthenium(III)-DMSO complexes with purine base derivatives. J Inorg Biochem (2004) 0.78
Stem cells and cardiovascular repair: a role for natural and synthetic molecules harboring differentiating and paracrine logics. Cardiovasc Hematol Agents Med Chem (2008) 0.78